Semaglutide 2 mg Shows Lower MACE Risk Than Tirzepatide in T2D Study
Adults with type 2 diabetes taking semaglutide injection 1 mg who escalated to the 2 mg dose faced a modestly lower risk of major adverse cardiovascular events than patients who switched to tirzepatide, according to a real-world analysis presented at the European Association for the Study of Diabetes Annual Meeting 2026 in Milan, Italy.
- Semaglutide 2 mg escalation tied to a 6% lower major adverse cardiovascular events risk compared to tirzepatide switching.
- The retrospective claims analysis analyzed data from 185,705 adults escalating semaglutide and 23,104 patients switching to tirzepatide.
- Findings stem from the COMPETE SWITCH study funded by Novo Nordisk, utilizing Komodo Health’s Healthcare Map database.
Study Uses Komodo Health Database to Track Diabetes Medications
The retrospective claims study investigated clinical trajectories using Komodo Health’s Healthcare Map, a large US claims database integrated with linked laboratory results spanning from January 2018 to September 2025. Across a cohort of 636,525 adults with type 2 diabetes receiving semaglutide 1 mg, 29.2% escalated their dose to 2 mg within 365 days, while 3.6% switched to tirzepatide over the same period. By 720 days, those utilization figures shifted to 36.9% for dose escalation and 5.7% for medication switching.
Semaglutide Escalation Shows Lower Cardiovascular Event Risk
The cardiovascular outcomes analysis applied an intention-to-treat approach, evaluating 185,705 adults who escalated to semaglutide 2 mg against 23,104 patients who transitioned to tirzepatide. Major adverse cardiovascular events were defined composite-style to include all-cause death, myocardial infarction, or stroke. The resulting adjusted hazard ratio landed at 1.06 with a 95% confidence interval ranging from 1.04 to 1.08 and a P value of .005. Novo Nordisk characterized this statistical output as a 6% lower major adverse cardiovascular events risk favoring semaglutide escalation. A secondary subset analysis restricted to patients with more than one hemoglobin A1c or weight measurement at baseline yielded a consistent adjusted hazard ratio of 1.07 with a 95% confidence interval of 1.01 to 1.13.
The retrospective claims design prevents researchers from establishing direct cause and effect between medication choices and cardiovascular outcomes. The analysis did not assess safety outcomes, and the full study data remain unpublished, so clinicians must weigh these real-world findings cautiously when deciding whether to intensify a patient's current glucagon-like peptide-1 receptor agonist regimen or switch agents entirely.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.